Status:
COMPLETED
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Acute Hepatic Porphyria
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.
Eligibility Criteria
Inclusion
- Males and females aged \>/= 12 years
- Diagnosis of AHP \[acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP) and aminolevulinic acid dehydratase (ALAD) deficient porphyria (ADP)\]
- Porphyria attacks in the past 12 months or receiving treatment to prevent attacks
- Willing to provide written informed consent, medical records, and to comply with study requirements
Exclusion
- • Current participation in a clinical trial of an investigational product
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 26 2021
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT02240784
Start Date
August 1 2014
End Date
April 26 2021
Last Update
May 17 2021
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
San Francisco, California, United States, 94143
2
Clinical Trial Site
Miami, Florida, United States, 33136
3
Clinical Trial Site
Ann Arbor, Michigan, United States, 48109
4
Clinical Trial Site
New York, New York, United States, 10029